Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain

[1]  Alison I. Bernstein,et al.  Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  G. Miller,et al.  Selective Enhancement of Dopamine Release in the Ventral Pallidum of Methamphetamine-Sensitized Mice , 2016, ACS chemical neuroscience.

[3]  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration , 2016, Experimental Neurology.

[4]  A. Naranjo,et al.  Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children’s Oncology Group , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  G. Miller,et al.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. , 2015, ACS chemical neuroscience.

[6]  A. Bonci,et al.  Dopaminergic and glutamatergic microdomains within a subset of rodent mesoaccumbens axons , 2016 .

[7]  G. Miller,et al.  VMAT2 and Parkinson’s disease: harnessing the dopamine vesicle , 2014, Expert review of neurotherapeutics.

[8]  Laura M. Vecchio,et al.  Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo , 2014, Proceedings of the National Academy of Sciences.

[9]  C. Cavada,et al.  Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum , 2014, The Journal of Neuroscience.

[10]  G. Miller,et al.  Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus , 2014, Neuropharmacology.

[11]  Alison I. Bernstein,et al.  Vesicular Integrity in Parkinson’s Disease , 2013, Current Neurology and Neuroscience Reports.

[12]  H. Jinnah,et al.  Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia , 2012, Neurobiology of Disease.

[13]  J. Cadet,et al.  Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ , 2012, Behavioural Brain Research.

[14]  K. Wimalasena.  Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry , 2011, Medicinal research reviews.

[15]  G. Miller,et al.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease , 2011, Parkinson's disease.

[16]  K. Kaibuchi,et al.  Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal region of genetic animal model of schizophrenia , 2010, Synapse.

[17]  R. Kvetňanský,et al.  Vesicular Monoamine Transporters (VMATs) in Adrenal Chromaffin Cells: Stress-Triggered Induction of VMAT2 and Expression in Epinephrine Synthesizing Cells , 2010, Cellular and Molecular Neurobiology.

[18]  G. Miller,et al.  Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity , 2009, The Journal of Neuroscience.

[19]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[20]  Manuel Rodriguez,et al.  Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging , 2008, Neurobiology of Aging.

[21]  P. Emson,et al.  Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis , 2008, Journal of neurochemistry.

[22]  P. Emson,et al.  Altered vesicular dopamine storage in Parkinson's disease: a premature demise , 2008, Trends in Neurosciences.

[23]  F. Fonnum,et al.  Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. , 2008, Annual review of pharmacology and toxicology.

[24]  Gary W. Miller,et al.  Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration , 2007, The Journal of Neuroscience.

[25]  M. Schäfer,et al.  Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat , 2007, Journal of Molecular Neuroscience.

[26]  M. Schäfer,et al.  Reserpine- and tetrabenazine-sensitive transport of3H-histamine by the neuronal isoform of the vesicular monoamine transporter , 2007, Journal of Molecular Neuroscience.

[27]  G. Miller,et al.  Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  N. von Wurmb-Schwark,et al.  Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  M. Anlauf,et al.  The Vesicular Monoamine Transporter 2 (VMAT2) Is Expressed by Normal and Tumor Cutaneous Mast Cells and Langerhans Cells of the Skin but Is Absent from Langerhans Cell Histiocytosis , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  M. Schäfer,et al.  The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine , 2004, Pflügers Archiv.

[31]  A. Cuello,et al.  Production and immunocytochemical application of a highly sensitive and specific monoclonal antibody against rat dopamine-β-hydroxylase , 2004, Histochemistry.

[32]  G. Klöppel,et al.  Expression of the Two Isoforms of the Vesicular Monoamine Transporter (VMAT1 and VMAT2) in the Endocrine Pancreas and Pancreatic Endocrine Tumors , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  Lian Zhang,et al.  Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. , 2003, The American journal of psychiatry.

[34]  Gary W Miller,et al.  L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. , 2002, Neurotoxicology.

[35]  T. Montine,et al.  Enhancement of Dopaminergic Neurotoxicity by the Mercapturate of Dopamine , 2000, Journal of neurochemistry.

[36]  K. Fujiwara,et al.  Histamine monoclonal antibody for brain immunocytochemistry. , 1999, Journal of biochemistry.

[37]  D. Mash,et al.  Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease , 1999, Experimental Neurology.

[38]  O. Hornykiewicz.  Biochemical aspects of Parkinson's disease , 1998, Neurology.

[39]  A. Levey,et al.  Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.

[40]  Fei Xu,et al.  Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine , 1997, Neuron.

[41]  E. Pothos,et al.  Vesicular Transport Regulates Monoamine Storage and Release but Is Not Essential for Amphetamine Action , 1997, Neuron.

[42]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  F. Zhou,et al.  Serotonin transporter antibodies: production, characterization, and localization in the brain. , 1996, Brain research. Molecular brain research.

[44]  T. Bonner,et al.  Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Edwards,et al.  Differential expression of two vesicular monoamine transporters , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[46]  M Linial,et al.  Vesicular neurotransmitter transporters: from bacteria to humans. , 1995, Physiological reviews.

[47]  S. Hersch,et al.  The dopamine transporter: immunochemical characterization and localization in brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  R. Edwards,et al.  Chapter 26 The transport of neurotransmitters into synaptic vesicles , 1995 .

[49]  J. Henry,et al.  Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. , 1994, The Journal of experimental biology.

[50]  B. Hoffman,et al.  Expression cloning of a reserpine-sensitive vesicular monoamine transporter. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Sulzer,et al.  Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  R. Edwards.  The transport of neurotransmitters into synaptic vesicles , 1992, Current Opinion in Neurobiology.

[53]  D. Eisenberg,et al.  A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter , 1992, Cell.

[54]  S. Goldberg,et al.  Cocaine self-administration appears to be mediated by dopamine uptake inhibition , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[55]  H. V. van Praag,et al.  Effect of tyrosine on attention deficit disorder with hyperactivity. , 1988, The Journal of clinical psychiatry.

[56]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[57]  J. Bonnar,et al.  Letter: Prostaglandins and pre-eclampsia. , 1974, Lancet.

[58]  G. Paulson,et al.  Levodopa in the presymptomatic diagnosis of Huntington's chorea. , 1972, Lancet.

[59]  E. Freis.  Mental depression in hypertensive patients treated for long periods with large doses of reserpine. , 1954, The New England journal of medicine.